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A perspective for sequencing familial hypercholesterolaemia in
African Americans
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African Americans suffer disproportionately from poor cardiovascular health outcomes despite similar proportions of African
Americans and Americans of European ancestry experiencing elevated cholesterol levels. Some of the variation in cardiovascular
outcomes is due to confounding effects of other risk factors, such as hypertension and genetic inﬂuence. However, genetic variants
found to contribute to variation in serum cholesterol levels in populations of European ancestry are less likely to replicate in
populations of African ancestry. To date, there has been limited follow-up on variant discrepancies or on identifying variants that
exist in populations of African ancestry. African and African-American populations have the highest levels of genetic heterogeneity,
which is a factor that must be considered when evaluating genetic variants in the burgeoning era of personalised medicine. Many
of the large published studies identifying genetic variants associated with disease risk have evaluated populations of mostly
European ancestry and estimated risk in other populations based on these ﬁndings. The purpose of this paper is to provide a
perspective, using familial hypercholesterolaemia as an exemplar, that studies evaluating genetic variation focused within minority
populations are necessary to identify factors that contribute to disparities in health outcomes and realise the full utility of
personalised medicine.
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INTRODUCTION
A recent article postulates that race should be eliminated from
genetic research in favour of focusing on ancestry.1 We agree that
race, is a primarily social construct that if used for genetic research
has the potential to perpetuate ineffective treatment in the clinical
setting, and that using ancestry informative makers for genetic
analysis is required for robust analysis that replicates between
studies. However, there has been a general lack of inclusion of
ethnic minority populations in studies evaluating the genetic
contribution to complex disease aetiology2 despite known
signiﬁcant genetic variation by ancestry.3,4 Furthermore, African
Americans suffer disproportionately from a variety of poor health
outcomes, from preterm birth5 to cardiovascular disease,6 and
neither social nor genetic variation independently explain these
disparities.7–11 The crux of the issue we wish to elucidate is that
the genetic variation speciﬁcally within African-American popula-
tions that contribute to disparities in health outcomes, like
cardiovascular disease, is largely unrecognised and understudied.
Here we will describe a gap in knowledge regarding genetic
markers related to blood lipid levels and familial hypercholester-
olaemia (FH) as an exemplar of limited understanding of the
genetic variation that may contributes to health disparities within
the African-American population.
FAMILIAL HYPERCHOLESTEROLAEMIA
FH is an autosomal dominant disorder that is characterised by
extremely high levels of low-density lipoprotein cholesterol resulting
in cholesterol deposits in tendons and premature cardiovascular
disease. The frequency of FH is now believed to be ~1 in 200 in
most populations.12 More than 90% of mutations that cause FH are
loss of function mutations in the low-density lipoprotein receptor
(LDLR) gene (OMIM # 143890); and most of the remaining cases
have mutations in apolipoprotein B (APOB, OMIM # 107730) or
proprotein convertase subtilisin-like kexin type 9 (PCSK9, OMIM #
603776). However, the number of individuals identiﬁed with FH in
most populations, including the United States, is only ~ 1% of
affected individuals. This is a particularly serious lapse in screening
since ~2% of sudden myocardial infarction deaths in males under
50 and females under 60 are the consequence of heterozygous FH
and are preventable with statin therapy.12
A working group of cardiologists recently made a consensus
recommendation emphasising the urgent worldwide need for
diagnostic screening for FH.12 Populations in Norway and the
Netherlands are screened, diagnosed and treated at a rate
between 43–71%, while screening in other nations generally
remains below 1% and it is unclear how may individuals of African
ancestry are screened.12 These alarmingly low numbers of
individuals screened for FH, particularly those not of European
ancestry, places many at risk from early morbidity and mortality
unnecessarily. Furthermore, it should be noted that most
countries do not collect information on the prevalence of FH
and estimates for various populations, not including those of
African ancestry, were made based on European populations for
the recommendations developed for FH screening.
As described by Yudell et al.,1 using race as a proxy in genetic
studies and to evaluate disease risk may lead to the incorrect
assumption that certain populations are unaffected or do not carry
certain genetic risk variants. FH is a tangible example of this
particular issue. Indeed African Americans suffer from FH,
although African Americans that present with FH are less likely
to have a known FH pathogenic variants associated with their
condition identiﬁed when they have diagnostic sequencing.13,14 In
fact, 77% of African Americans that presented with autosomal
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dominant hypercholesterolaemia did not carry any of the known
risk alleles in the three genes commonly associated with FH.13 This
suggests that genetic risk variants for FH in populations of African
ancestry are different than those of European ancestry and have
not yet been identiﬁed. It is unclear whether studies evaluating FH
in populations of African ancestry have not been completed or if
they were excluded for other reasons.
GENETIC CONTRIBUTION OF VARIATION IN SERUM LIPID
LEVELS
Nearly one third of adults in the United States have elevated
cholesterol levels and almost half of the people affected have total
cholesterol levels above 240 mg/dl.15 Less than half of affected
individuals are receiving treatment; and of those who are, only
one third have their condition under control.16 African-American
populations consistently have lower total cholesterol and
triglyceride levels and higher high-density lipoprotein levels
(‘good’ cholesterol) relative to other ethnicities in the United
States, but approximate those of European ancestry.16,17
Worldwide, African populations have the lowest burden of
hypercholesterolaemia of all global regions and African Americans
may share some variants that have a protective role.18,19 However,
the higher high-density lipoprotein levels observed in African
Americans does not confer the same protective effect related to
heart disease as seen in other populations because African
Americans continue to experience earlier onset of cardiovascular-
related disease and suffer worse outcomes.7 These outcomes
could be related to the higher prevalence of other cardiovascular
risk factors in African Americans, such as hypertension and
obesity, although ancestry is a potential confounder.
African and African-American populations have the highest
levels of genetic heterogeneity,20 which is a factor that must be
considered in the burgeoning era of personalised medicine. For
example, in previous genome-wide association studies (GWAS)
that evaluated the association between serum cholesterol and
triglycerides levels with single-nucleotide polymorphisms (SNPs),
SNPs that were signiﬁcant in a population of European ancestry
were less likely to replicate in those of African ancestry compared
with Asian and East Asian populations.21 Some of this discrepancy
may be due to variation in allele frequencies between populations
of European and African ancestry. Of the 163 SNPs that were
found to be signiﬁcantly associated with altered serum cholesterol
and triglycerides in two GWAS studies,21,22 30 of the SNPs minor
allele frequencies are reversed (i.e., the minor in European
populations is the major allele in African populations) and 15
SNPs have minor allele frequency of o5% in African-American
populations (i.e., they are less prevalent in African than European
ancestry populations). Previous studies estimate that ancestry
informative genetic markers in African Americans more closely
approximate populations from West Africa (71%) than Europe
(13%), although the percentage of African ancestry is highly
variable within the African-American population.20 This variability
in percentage of African and European ancestry in African
Americans likely contribute to poor identiﬁcation/replication of
genetic markers associated with disease risk, because many of the
large genomic studies have been completed in cohorts represent-
ing mostly European ancestry populations. Conversely, genetic
variation associated with altered serum cholesterol levels have
also been associated with improved immunity in African
populations.19 This is a prime example why variation within
minority populations should be studied further, because some
genetic variants associated with evolutionary advantage in one
geographic location may not be as advantageous as in another.
Variation in individual serum cholesterol levels are also known
to be polygenic.21,23 Differences in combinations of contributing
alleles could also contribute to the lower levels of replication in
genetic studies between populations not of European or mixed
ancestry. For example, signiﬁcant SNPs from GWAS studies21,22
located within genes associated with FH have similar allele
frequencies in African Americans (ASW) and European Americans
(CEU) populations (rs6511720 (LDLR ASW=0.12, CEU= 0.1),
rs2413395 (APOB ASW=0.17 CEU= 0.33), and rs2479409 (PCSK9
ASW=0.32 CEU= 0.34); www.1000genomes.org). These particular
SNPs are not listed as pathogenic variants for FH, but contribute to
variation in serum cholesterol levels. Therefore, genomic variation
for FH among African Americans may be different than that
seen among European Americans, thereby necessitating further
examination of FH among this understudied population. If
scientists do not further explore the variation of FH among
African-American populations, many people with this genetic
predisposition may be missed and suffer grave clinical
consequences unnecessarily.
FUTURE DIRECTIONS
The value of genetic screening of adults for pathological genetic
variants, such as FH that cause serious pathological conditions, has
been demonstrated in principle, for a signiﬁcant number of
conditions.24 A barrier to the implementation of genetic screening
programmes is the cost/beneﬁt ratio for each individual pro-
gramme. Due to this, cascade screening has been successfully
implemented in European countries to successfully identify a
number of individuals with FH.12,25 This approach to identifying
affected individuals occurs once an individual is diagnosed with
FH, who becomes the proband, and subsequent family members
are screened based on relationship and medical history. However,
cascade testing is less effective when few probands for a
condition are known, such is the case for FH in the United
States.26 In addition, cascade screening results in identiﬁcation of
FH status at a much later age, and treatment should begin as early
as childhood for homozyogotes and heterozygotes with aggres-
sive FH presentation.25,26 Subsequently, the marked reduction in
cost of whole-genome sequencing (WGS) now makes it possible
to reduce the cost of sequence based screening for pathological
variants causing many different conditions by amortising the cost
of each condition screened as a fraction of the total sequence
cost. It is anticipated that WGS cost will drop further over the next
decade making the economics of WGS even more attractive for
this use compared with individual sequence panels for a subset of
genes relevant to a particular condition. WGS could be particularly
useful in identifying FH variants that are speciﬁc for populations of
African ancestry that have not yet been identiﬁed.13
Most genetic studies to date have viewed population structure as
a problem to be avoided in WGS, but with improved analysis
methods, we are interested in conducting case–control studies
within different ethnic groups as a way to increase power and
discover variants that inﬂuence phenotypes. Power to detect a
genetic variant that inﬂuences disease depends crucially on the
allele frequency of the variant, and different populations have
different allele frequencies due to demographic forces (e.g., due to
either genetic drift or natural selection). Others have developed
variations of ‘trans-ethnic’ meta-analysis approaches to better
identify associations of causal variants with phenotypic differences
by capitalising on variations in linkage disequilibrium by
ancestry.27–31 Wang et al.30 found trans-ethnic approaches that
utilise a Bayesian framework27 or more relaxed assumptions in a
random-effect model31 identify potential causal variants better that
traditional GWAS meta-analysis approaches in populations not of
European ancestry. However, Asimit et al.29 argue that including
more participants of African ancestry in the initial study design out
performs statistical meta-analysis approaches in ﬁne mapping of
genetic associations in populations not of European ancestry.
In analysis of rare variant effects on disease, such as FH, it is
essential to consider that these variants are likely to be population
speciﬁc and/or geographically restricted.32–38 For example,
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a common variant that inﬂuences diabetes risk in Greenland
increases disease risk 10-fold, but is essentially absent in the rest
of the world.39 This variant could be identiﬁed with a smaller
sample size than usually used in genetic studies because of its
large effect. Furthermore, utilising this approach will enable us to
also identify variants that may have protective health effects in
populations of African ancestry, as we have found with other
cardiovascular conditions.40 We suggest using African ancestry
cohorts and comparing results with diverse cohorts to search for
African ancestry population-speciﬁc strong effects that inﬂuence
health outcomes. Given that inclusion of more participants with
African ancestry improves ﬁne-mapping mapping of causal
variants,29 this may be the best approach to identify variants
speciﬁc to populations of African ancestry that are unknown.
CONCLUSION
Both environmental and genetic factors contribute to disparities in
health outcomes, although limited studies strive to identify
genetic variants within the African-American community that
contribute to poor outcomes. The genetic heterogeneity
within the population results in some overlap with multiple
populations. However, there may be variants unique to this
population that have not been identiﬁed or polygenic variants
that are unique to African-American populations due to mixed
ancestry. Personalised medicine aims to improved health out-
comes and in order to accomplish this goal, more studies
evaluating genomic variants related to disease—both known
and unknown—are direly necessary. We recommend that trans-
disciplinary scientists teams (nurses, physicians, genetic counsel-
lors and biostatisticians) mine GWAS and genome sequencing
studies with African-American participants to further explore
differences within African Americans for FH in order to truly
understand the genomic underpinnings of disease process in
order to devise targeted individualised therapeutics that will be
beneﬁcial in reducing health disparities and eliminating disease.23
Further genomic studies, particularly genome sequencing based,
that target larger numbers of African Americans are warranted in
order to advance understanding of FH disease process for
improved treatment and health outcomes.
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